Literature DB >> 20650892

A new mode of mineralocorticoid receptor antagonism by a potent and selective nonsteroidal molecule.

Jérôme Fagart1, Alexander Hillisch, Jessica Huyet, Lars Bärfacker, Michel Fay, Ulrich Pleiss, Elisabeth Pook, Stefan Schäfer, Marie-Edith Rafestin-Oblin, Peter Kolkhof.   

Abstract

Limitations of current steroidal mineralocorticoid receptor (MR) antagonists have stimulated the search for a new generation of molecules. We screened for novel nonsteroidal compounds and identified MR antagonists derived from the chemical class of dihydropyridines. Chemical optimization resulted in BR-4628, which displays high in vitro and in vivo MR potency as well as selectivity with respect to the other steroid hormone receptors and the L-type calcium channel. Biochemical studies demonstrated that BR-4628 forms complexes with MR that do not promote the recruitment of transcriptional co-regulators. Docking experiments, using the crystal structure of the MR ligand-binding domain in an agonist conformation, revealed that BR-4628 accommodates in the MR ligand-binding cavity differently in comparison with the classical steroidal MR antagonists. An alanine scanning mutagenesis approach, based on BR-4628 docking, allowed identifying its anchoring mode within the ligand-binding cavity. Altogether, we propose that BR-4628 is a bulky antagonist that inactivates MR through a passive mechanism. It represents the prototype of a new class of MR antagonists.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20650892      PMCID: PMC2943305          DOI: 10.1074/jbc.M110.131342

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  44 in total

Review 1.  Aldosterone and the heart: towards a physiological function?

Authors:  C Delcayre; J S Silvestre
Journal:  Cardiovasc Res       Date:  1999-07       Impact factor: 10.787

Review 2.  Dihydropyridine calcium channel blockers: basic pharmacological similarities but fundamental therapeutic differences.

Authors:  Peter A Meredith; Henry L Elliott
Journal:  J Hypertens       Date:  2004-09       Impact factor: 4.844

3.  RALES, EPHESUS and redox.

Authors:  John W Funder
Journal:  J Steroid Biochem Mol Biol       Date:  2005-01-28       Impact factor: 4.292

4.  Autosomal dominant pseudohypoaldosteronism type 1: mechanisms, evidence for neonatal lethality, and phenotypic expression in adults.

Authors:  David S Geller; Junhui Zhang; Maria-Christina Zennaro; Alberto Vallo-Boado; Juan Rodriguez-Soriano; Laszlo Furu; Robert Haws; Daniel Metzger; Barbara Botelho; Lefkothea Karaviti; Andrea M Haqq; Howard Corey; Sandra Janssens; Pierre Corvol; Richard P Lifton
Journal:  J Am Soc Nephrol       Date:  2006-04-12       Impact factor: 10.121

5.  Antagonism in the human mineralocorticoid receptor.

Authors:  J Fagart; J M Wurtz; A Souque; C Hellal-Levy; D Moras; M E Rafestin-Oblin
Journal:  EMBO J       Date:  1998-06-15       Impact factor: 11.598

Review 6.  Aldosterone regulation of gene transcription leading to control of ion transport.

Authors:  J D Horisberger; B C Rossier
Journal:  Hypertension       Date:  1992-03       Impact factor: 10.190

7.  Structural basis of spirolactone recognition by the mineralocorticoid receptor.

Authors:  Jessica Huyet; Grégory M Pinon; Michel R Fay; Jérôme Fagart; Marie-Edith Rafestin-Oblin
Journal:  Mol Pharmacol       Date:  2007-06-14       Impact factor: 4.436

8.  Efficacy and tolerance of spironolactone in essential hypertension.

Authors:  X Jeunemaitre; G Chatellier; C Kreft-Jais; A Charru; C DeVries; P F Plouin; P Corvol; J Menard
Journal:  Am J Cardiol       Date:  1987-10-01       Impact factor: 2.778

9.  Three new epoxy-spirolactone derivatives: characterization in vivo and in vitro.

Authors:  M de Gasparo; U Joss; H P Ramjoué; S E Whitebread; H Haenni; L Schenkel; C Kraehenbuehl; M Biollaz; J Grob; J Schmidlin
Journal:  J Pharmacol Exp Ther       Date:  1987-02       Impact factor: 4.030

Review 10.  The steroid and thyroid hormone receptor superfamily.

Authors:  R M Evans
Journal:  Science       Date:  1988-05-13       Impact factor: 47.728

View more
  40 in total

Review 1.  Key advances in antihypertensive treatment.

Authors:  Ludovit Paulis; Ulrike M Steckelings; Thomas Unger
Journal:  Nat Rev Cardiol       Date:  2012-03-20       Impact factor: 32.419

2.  Mineralocorticoid Receptor Antagonism in AKI: A New Hope?

Authors:  Luis A Juncos; Luis I Juncos
Journal:  J Am Soc Nephrol       Date:  2015-09-11       Impact factor: 10.121

3.  Topical Mineralocorticoid Receptor Blockade Limits Glucocorticoid-Induced Epidermal Atrophy in Human Skin.

Authors:  Eve Maubec; Cédric Laouénan; Lydia Deschamps; Van Tuan Nguyen; Isabelle Scheer-Senyarich; Anne-Catherine Wackenheim-Jacobs; Maud Steff; Stéphanie Duhamel; Sarah Tubiana; Nesrine Brahimi; Stéphanie Leclerc-Mercier; Béatrice Crickx; Claudine Perret; Selim Aractingi; Brigitte Escoubet; Xavier Duval; Philippe Arnaud; Frederic Jaisser; France Mentré; Nicolette Farman
Journal:  J Invest Dermatol       Date:  2015-02-10       Impact factor: 8.551

Review 4.  Endogenous cardiotonic steroids in kidney failure: a review and an hypothesis.

Authors:  John M Hamlyn; Paolo Manunta
Journal:  Adv Chronic Kidney Dis       Date:  2015-05       Impact factor: 3.620

Review 5.  Novel drugs and intervention strategies for the treatment of chronic kidney disease.

Authors:  Hiddo Jan Lambers Heerspink; Dick de Zeeuw
Journal:  Br J Clin Pharmacol       Date:  2013-10       Impact factor: 4.335

Review 6.  Aldosterone excess and resistant hypertension: investigation and treatment.

Authors:  Michael Stowasser
Journal:  Curr Hypertens Rep       Date:  2014-07       Impact factor: 5.369

7.  The mineralocorticoid receptor promotes fibrotic remodeling in atrial fibrillation.

Authors:  Daniel Lavall; Christian Selzer; Pia Schuster; Matthias Lenski; Oliver Adam; Hans-Joachim Schäfers; Michael Böhm; Ulrich Laufs
Journal:  J Biol Chem       Date:  2014-01-27       Impact factor: 5.157

Review 8.  Mineralocorticoid receptors in vascular disease: connecting molecular pathways to clinical implications.

Authors:  Adam P McGraw; Amy McCurley; Ioana R Preston; Iris Z Jaffe
Journal:  Curr Atheroscler Rep       Date:  2013-07       Impact factor: 5.113

Review 9.  Management of hyperkalaemia consequent to mineralocorticoid-receptor antagonist therapy.

Authors:  Sara S Roscioni; Dick de Zeeuw; Stephan J L Bakker; Hiddo J Lambers Heerspink
Journal:  Nat Rev Nephrol       Date:  2012-10-16       Impact factor: 28.314

Review 10.  Is there a new dawn for selective mineralocorticoid receptor antagonism?

Authors:  James M Luther
Journal:  Curr Opin Nephrol Hypertens       Date:  2014-09       Impact factor: 2.894

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.